logo
66-million-year-old vomit found in Denmark: 'Most famous piece of puke in the world'

66-million-year-old vomit found in Denmark: 'Most famous piece of puke in the world'

USA Today28-01-2025

Vomit normally isn't celebrated, or something people ogle over, but exceptions can seemingly be made when it is 66 million years old.
Peter Bennicke, a local fossil hunter, discovered the blob of vomit at the Cliffs of Stevns, a UNESCO-listed geological site on the Danish island of Zealand that's comprised of about 9 miles of fossil-rich coastal cliff, the Museum of East Zealand said in a news release.
Danish officials said the fossil belonged to an animal, and the contents of the vomit contained sea lily remains. Dutch sea lily expert John Jagt concluded that the throw-up consisted of two different species of sea lilies mixed into a clump and that the creatures were eaten by another animal that had subsequently regurgitated the indigestible skeletal parts of their bodies, according to the release.
"It is truly an unusual find. Sea lilies are not a particularly nutritious diet, as they mainly consist of calcareous plates held together by very few soft parts," Jesper Milàn, a Danish paleontologist and curator of Geology at Geomuseum Faxe, said in the release.
What does the vomit's discovery mean?
Milàn predicted that a fish ate the sea lilies that were living at the bottom of the Cretaceous Sea, which according to the Utah State University Prehistoric Museum, was a narrow and shallow sea that connected the modern Gulf of Mexico and the modern Arctic Ocean.
The vomit's discovery provides important and new knowledge about the relationship between predators and prey, and the food chains in the Cretaceous Sea, Milàn said.
According to UNESCO, the Cliffs of Stevns contain "exceptional evidence of the impact of the Chicxulub meteorite that crashed into the planet about 65 million years ago," which is commonly believed to have caused the extinction of dinosaurs.
Sea lilies, also known as crinoids, have declined in diversity since their kind peaked about 300 million years ago, but over 650 living species are known, and they remain abundant in many marine habitats ranging from shallow coral reefs to the floors of oceanic trenches, the National Oceanic and Atmospheric Administration said.
The vomit can be viewed at a Denmark museum
The throw-up is also classified as "Danekræ," which is a designation for Danish objects of 'exceptional natural historical value.' This means the vomit belongs to Denmark and not its finder, Bennicke, so it must be turned over to a natural history museum.
The vomit will be placed in a small special exhibition at the Geomuseum Faxe Museum in Faxe, Denmark during the winter holidays for people to view, according to the release.
Milàn called the vomit "the most famous piece of puke in the world," the New York Times reported.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca signs $5 billion research deal with China's CSPC
AstraZeneca signs $5 billion research deal with China's CSPC

Yahoo

time2 days ago

  • Yahoo

AstraZeneca signs $5 billion research deal with China's CSPC

(Reuters) -AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under the agreement, the two companies will collaborate to discover and develop pre-clinical candidates for potential treatments targeting chronic diseases, with CSPC conducting AI-driven research in Shijiazhuang City. Cambridge, UK-based AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion in development milestones and $3.6 billion in sales-related milestones, AstraZeneca said. In March, AstraZeneca announced plans to invest $2.5 billion in a research and development hub in Beijing, as it works to rebuild trust in its second-largest market.

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year

Yahoo

time3 days ago

  • Yahoo

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year

(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January. Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial. Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone. The company has launched a new late-stage trial for the drug, the U.S. government's trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies. Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly may be gaining an edge over the company in the market for such drugs.

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

Yahoo

time3 days ago

  • Yahoo

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said. CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT. The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. GERMAN BIOTECH CHAMPION The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress. CureVac shares were worth as much as 120 euros in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at 4.65 euros. BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac. The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer. ($1 = 0.8624 euros) (Additional reporting by Christian Kraemer; Editing by Friederike Heine, Jan Harvey and Emelia Sithole-Matarise)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store